Abstract
This study details the synthesis of a series of fluoroquinolone C3-oxadiazole-thione Mannich base derivatives (6a–6j) designed as antitumor agents. By utilizing an oxadiazole-thione heterocycle as an electronic isostere for the C3 carboxyl group of Pefloxacin (1), researchers aimed to enhance cytotoxicity against cancer cells. The target compounds were synthesized via hydrazide formation, ring closure, and a final aminomethylation (Mannich reaction). Structural confirmation was achieved through elemental analysis, $^1$H NMR, and mass spectrometry. Biological evaluation using the MTT assay against human hepatoma (Hep-3B) cells revealed that all ten target compounds significantly outperformed the parent antibiotic, with aliphatic amine derivatives demonstrating the highest potency.
Introduction
Fluoroquinolones (FQs) are established broad-spectrum antibiotics that inhibit bacterial DNA topoisomerases. Due to the structural homology between bacterial and mammalian topoisomerases, FQs have emerged as promising scaffolds for anticancer drug development. However, the C3 carboxyl group, while essential for antibacterial efficacy, often hinders antitumor activity. This research explores the bioisosteric replacement of the C3 carboxyl group with an oxadiazole-thione Mannich base to shift the pharmacological profile from antibacterial to antitumor.
Synthesis and Methodology
The synthesis of the target compounds (6a–6j) proceeded from the parent fluoroquinolone, Pefloxacin (1), through a multi-step sequence. Initially, Pefloxacin was converted to a hydrazide intermediate (2) via reaction with hydrazine hydrate under reflux. Subsequent treatment with carbon disulfide ($CS_2$) and potassium carbonate ($K_2CO_3$) facilitated the formation of the oxadiazole-thione ring at the C3 position, yielding intermediate 4.
The final target compounds were obtained through a Mannich reaction, where intermediate 4 reacted with formaldehyde and various secondary amines or substituted anilines. This process introduced diverse aminomethyl groups, creating a library of ten derivatives (6a–6j) for biological testing.
Results and Discussion
The antitumor potential of the synthesized derivatives was assessed using the MTT assay against the human liver cancer cell line Hep-3B. Pefloxacin (1) served as a negative control, showing minimal activity ($IC_{50} > 150\ \mu mol/L$).
Potency and Structure-Activity Relationships (SAR)
All target compounds (6a–6j) exhibited significantly enhanced inhibitory activity compared to the parent drug. Key findings include:
- Superior Potency: Compound 6a, featuring a dimethylamine Mannich base, was the most active with an $IC_{50}$ of 8.4 $\mu mol/L$, nearly 18 times more potent than Pefloxacin.
- Amine Substituent Effects: A clear SAR trend was observed where derivatives with aliphatic amines (e.g., dimethylamine, piperazine) were more active than those with aromatic amines (substituted anilines).
- Intermediate Comparison: The target Mannich bases showed markedly higher activity than the intermediate oxadiazole-thione 4 ($IC_{50} = 84.3\ \mu mol/L$), confirming that the aminomethylation step is critical for maximizing antitumor efficacy.
Several compounds (6a, 6d, 6e) achieved activity levels comparable to the reference anticancer drug Bisantrene ($IC_{50} = 12.3\ \mu mol/L$), validating the design strategy of using oxadiazole-thione Mannich bases as C3 carboxyl isosteres.
Conclusion
The replacement of the C3 carboxyl group in Pefloxacin with an oxadiazole-thione Mannich base successfully transformed a standard antibiotic into a potent antitumor agent. The resulting derivatives showed high cytotoxicity against Hep-3B liver cancer cells, with aliphatic amine substitutions providing the best results. These findings suggest that C3-isostere modification is a viable pathway for developing new fluoroquinolone-based cancer therapies. Future studies should expand testing to a broader range of cancer cell lines and investigate the underlying molecular mechanisms of action.
Summary updated